Table 1.
Baseline characteristics study cohort
| Patients (n = 27) | Healthy controls (n = 27) | |
|---|---|---|
| Mean age (SD) | 41.6 (12.8) | 46.7 (4.7) |
| # Male (%) | 18 (66.7) | 10 (37.0) |
| Mean z-score broadband power (SD) | 0.0 (0.9) | 0.0 (1.0) |
| # Patients with grade II glioma (%) | 13 (48.1) | |
| # Patients with grade III glioma (%) | 7 (25.9) | |
| # Patients with grade IV glioma (%) | 7 (25.9) | |
| IDH/1p19q status | ||
| # Tumors with IDH-mut/1p19q codeletion (%) | 6 (22.2) | |
| # Tumors with IDH-mut/1p19q non-codeletion (%) | 14 (51.9) | |
| # Tumors with IDH-wt (%) | 7 (25.9) | |
| # Patients with epilepsy (%) | 21 (77.8) | |
| # Patients using AEDs (%) | 21 (77.8) | |
| # Patients treated with radiotherapy (%) | 24 (88.9) | |
| # Patients treated with chemotherapy (%) | 17 (63.0) | |
| Median KPS [range] | 100 [70–100] | |
| Median # weeks between resection and MEG [range] | 22 [3–94] | |
| Median # weeks PFS or loss to follow-up [range] | 75 [0–376] | |
| Median # weeks of OS or loss to follow-up (n = 38, [range]) | 276 [6–372] | |
| # Patients with tumor progression (%) | 20 (74.1) | |
| # Patients who died (%) | 11 (40.7) |
AED antiepileptic drug, IDH isocitrate dehydrogenase, KPS Karnofsky performance score, OS overall survival, PFS progression-free survival, SD standard deviation, WT wildtype